BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for imp...BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for improving efficacy and outcomes in aGC patients.AIM To determine the efficacy and safety of cetuximab(CET)combined with the FOLFOX4 regimen(infusional fluorouracil,folinic acid,and oxaliplatin)as firstline therapy for patients with aGC,who received evidence-based care(EBC).METHODS A total of 117 aGC patients who received EBC from March 2019 to March 2022 were enrolled.Of these,60 in the research group(RG)received CET+FOLFOX4 as first-line therapy,whereas 57 in the control group(CG)received FOLFOX4.The efficacy[clinical response rate(RR)and disease control rate(DCR)],safety(liver and kidney dysfunction,leukopenia,thrombocytopenia,rash,and diarrhea),serum tumor marker expression[STMs;carbohydrate antigen(CA)19-9,CA72-4,and carcinoembryonic antigen(CEA)],inflammatory indicators[interleukin(IL)-2 and IL-10],and quality of life(QOL)of the two groups were compared.RESULTS A markedly higher RR and DCR were observed in the RG compared with the CG,with an equivalent safety profile between the two groups.RG exhibited notably reduced CA19-9,CA72-4,CEA,and IL-2 levels following treatment,which were lower than the pre-treatment levels and those in the CG.Post-treatment IL-10 was statistically increased in RG,higher than the pre-treatment level and the CG.Moreover,a significantly improved QOL was evident in the RG.CONCLUSION The CET+FOLFOX4 regimen is highly effective as first-line treatment for aGC patients receiving EBC.It facilitates the suppression of STMs,ameliorates the serum inflammatory microenvironment,and enhances QOL,without increased adverse drug effects.展开更多
Objective To analyze the efficacy and safety of Rh-endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer.Methods All 60 metastatic colorectal cancer patients were divided into the test...Objective To analyze the efficacy and safety of Rh-endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer.Methods All 60 metastatic colorectal cancer patients were divided into the test group(n = 30) and the control group(n = 30). The control group was treated with chemotherapy regime FOLFOX4(Oxaliplatin + Fluorouracil + Calcium Levofolinate), the test group was treated by Endostar combined with FOLFOX4 scheme.Results The response rates were 53.3% in test group and 36.7% in control group respectively(P < 0.05), the disease control rate were 83.3% and 73.3%(P < 0.05). The median progression-free survival in test group and control group were 7.3 months versus 5.3 months(P < 0.05) and median overall survival were 11.6 months versus 9.3 months(P < 0.05). Among 27 cases of liver metastases were sub group analysis, difference on the test group and the control group response rate(RR) and disease control rate(DCR) had statistical significance(P < 0.05), but difference on progression free survival(PFS) and overall survival(OS) had no statistical significance(P > 0.05). The major toxicities were myelosuppression, gastrointestinal symptoms, neurotoxicity, most in grade I-II. After chemotherapy, quality of life(QOL) of patients were more improved than before treatment. After treatment the carcino embryonie antigen(CEA) and caner antigent 199(CA199) levels decreased obviously, furthermore, the test group decreased more obviously than the control group. Conclusion Rh-endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer is safer and effective, and also improves PFS.展开更多
文摘BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for improving efficacy and outcomes in aGC patients.AIM To determine the efficacy and safety of cetuximab(CET)combined with the FOLFOX4 regimen(infusional fluorouracil,folinic acid,and oxaliplatin)as firstline therapy for patients with aGC,who received evidence-based care(EBC).METHODS A total of 117 aGC patients who received EBC from March 2019 to March 2022 were enrolled.Of these,60 in the research group(RG)received CET+FOLFOX4 as first-line therapy,whereas 57 in the control group(CG)received FOLFOX4.The efficacy[clinical response rate(RR)and disease control rate(DCR)],safety(liver and kidney dysfunction,leukopenia,thrombocytopenia,rash,and diarrhea),serum tumor marker expression[STMs;carbohydrate antigen(CA)19-9,CA72-4,and carcinoembryonic antigen(CEA)],inflammatory indicators[interleukin(IL)-2 and IL-10],and quality of life(QOL)of the two groups were compared.RESULTS A markedly higher RR and DCR were observed in the RG compared with the CG,with an equivalent safety profile between the two groups.RG exhibited notably reduced CA19-9,CA72-4,CEA,and IL-2 levels following treatment,which were lower than the pre-treatment levels and those in the CG.Post-treatment IL-10 was statistically increased in RG,higher than the pre-treatment level and the CG.Moreover,a significantly improved QOL was evident in the RG.CONCLUSION The CET+FOLFOX4 regimen is highly effective as first-line treatment for aGC patients receiving EBC.It facilitates the suppression of STMs,ameliorates the serum inflammatory microenvironment,and enhances QOL,without increased adverse drug effects.
基金Supported by a grant from the Nation Natural Sciences Foundation of China(No.8127400)
文摘Objective To analyze the efficacy and safety of Rh-endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer.Methods All 60 metastatic colorectal cancer patients were divided into the test group(n = 30) and the control group(n = 30). The control group was treated with chemotherapy regime FOLFOX4(Oxaliplatin + Fluorouracil + Calcium Levofolinate), the test group was treated by Endostar combined with FOLFOX4 scheme.Results The response rates were 53.3% in test group and 36.7% in control group respectively(P < 0.05), the disease control rate were 83.3% and 73.3%(P < 0.05). The median progression-free survival in test group and control group were 7.3 months versus 5.3 months(P < 0.05) and median overall survival were 11.6 months versus 9.3 months(P < 0.05). Among 27 cases of liver metastases were sub group analysis, difference on the test group and the control group response rate(RR) and disease control rate(DCR) had statistical significance(P < 0.05), but difference on progression free survival(PFS) and overall survival(OS) had no statistical significance(P > 0.05). The major toxicities were myelosuppression, gastrointestinal symptoms, neurotoxicity, most in grade I-II. After chemotherapy, quality of life(QOL) of patients were more improved than before treatment. After treatment the carcino embryonie antigen(CEA) and caner antigent 199(CA199) levels decreased obviously, furthermore, the test group decreased more obviously than the control group. Conclusion Rh-endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer is safer and effective, and also improves PFS.
